Quick Answer
VYNE Therapeutics Inc. reported Total Revenue of $570.0 thousand for fiscal year 2025.
VYNE Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $570.0K +13.8% |
$501.0K +18.2% |
$424.0K -11.1% |
$477.0K -48.8% |
$931.0K -95.6% |
$20.99M +4638.8% |
| Revenue (ASC 606) | $570.0K +13.8% |
$501.0K +18.2% |
$424.0K -11.1% |
$477.0K -48.8% |
$931.0K -95.6% |
$20.99M +4638.8% |
| Net Income | -$26.48M +33.5% |
-$39.83M -40.0% |
-$28.45M -22.6% |
-$23.21M +68.3% |
-$73.33M +71.3% |
-$255.57M -168.5% |
| Diluted EPS | -$0.62 +33.3% |
-$0.93 +66.5% |
-$2.78 +61.8% |
-$7.28 +71.6% |
-$25.64 -425.4% |
$7.88 |
| Total Assets | $30.16M -54.9% |
$66.91M -31.5% |
$97.69M +139.7% |
$40.76M -39.2% |
$67.05M -28.5% |
$93.74M +15.5% |
| Cash and Equivalents | $24.03M +20.6% |
$19.93M -34.9% |
$30.62M -0.9% |
$30.91M -26.8% |
$42.25M -26.6% |
$57.56M +31.5% |
| Long-Term Debt | — | — | — | — | $0.00 -100.0% |
$33.17M +1.4% |
| Stockholders Equity | $27.77M -46.7% |
$52.09M -41.3% |
$88.73M +184.4% |
$31.20M -35.8% |
$48.64M +29.7% |
$37.49M +113.3% |
| R&D Expense | $19.24M -37.8% |
$30.95M +89.8% |
$16.31M -11.3% |
$18.39M -5.9% |
$19.54M -55.1% |
$43.53M -15.0% |
| Operating Income | -$29.75M +31.8% |
-$43.64M -49.1% |
-$29.26M +14.7% |
-$34.30M +11.9% |
-$38.91M +84.6% |
-$252.55M -163.4% |
| Shares Outstanding | 33.32M +124.7% |
14.83M +5.2% |
14.10M +336.5% |
3.23M +8.5% |
2.98M -93.1% |
43.21M +373.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2025 | $69.0K | -65.2% | -65.8% |
| Revenue (ASC 606) | June 30, 2025 | $69.0K | -65.2% | -65.8% |
| Net Income | June 30, 2025 | -$5.75M | +38.8% | +33.2% |
| Diluted EPS | June 30, 2025 | -$0.13 | +40.9% | +35.0% |
| Total Assets | June 30, 2025 | $44.72M | -48.4% | -20.7% |
| Cash and Equivalents | June 30, 2025 | $22.05M | -25.5% | -21.8% |
| Long-Term Debt | September 30, 2021 | $0.00 | -100.0% | — |
| Stockholders Equity | June 30, 2025 | $38.88M | -48.1% | -11.9% |
| R&D Expense | June 30, 2025 | $4.88M | -33.2% | -20.3% |
| Operating Income | June 30, 2025 | -$7.54M | +27.5% | +18.0% |
| Shares Outstanding | June 30, 2025 | 19.77M | +36.0% | +23.9% |
- VYNE Therapeutics Inc. reported Total Revenue of $570.0 thousand for fiscal year 2025.
- VYNE Therapeutics Inc. showed an increase of +13.8% in Total Revenue compared to the prior fiscal year.
- VYNE Therapeutics Inc. reported Revenue (ASC 606) of $570.0 thousand for fiscal year 2025.
- VYNE Therapeutics Inc. showed an increase of +13.8% in Revenue (ASC 606) compared to the prior fiscal year.
- VYNE Therapeutics Inc. reported Net Income of -$26.48 million for fiscal year 2025.
- VYNE Therapeutics Inc. showed an increase of +33.5% in Net Income compared to the prior fiscal year.
- VYNE Therapeutics Inc. reported Diluted EPS of $0.62 per share (loss) for fiscal year 2025.
- VYNE Therapeutics Inc. showed an increase of +33.3% in Diluted EPS compared to the prior fiscal year.
- VYNE Therapeutics Inc. reported Total Assets of $30.16 million for fiscal year 2025.
- VYNE Therapeutics Inc. showed a decrease of -54.9% in Total Assets compared to the prior fiscal year.
- VYNE Therapeutics Inc. reported Cash and Equivalents of $24.03 million for fiscal year 2025.
- VYNE Therapeutics Inc. showed an increase of +20.6% in Cash and Equivalents compared to the prior fiscal year.
- VYNE Therapeutics Inc. reported Long-Term Debt of $0.00 for fiscal year 2021.
- VYNE Therapeutics Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- VYNE Therapeutics Inc. reported Stockholders Equity of $27.77 million for fiscal year 2025.
- VYNE Therapeutics Inc. showed a decrease of -46.7% in Stockholders Equity compared to the prior fiscal year.
- VYNE Therapeutics Inc. reported R&D Expense of $19.24 million for fiscal year 2025.
- VYNE Therapeutics Inc. showed a decrease of -37.8% in R&D Expense compared to the prior fiscal year.
- VYNE Therapeutics Inc. reported Operating Income of -$29.75 million for fiscal year 2025.
- VYNE Therapeutics Inc. showed an increase of +31.8% in Operating Income compared to the prior fiscal year.
- VYNE Therapeutics Inc. reported Shares Outstanding of 33.32 million shares for fiscal year 2025.
- VYNE Therapeutics Inc. showed an increase of +124.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: